{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:20:08Z","timestamp":1787026808673,"version":"build-2736575974"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although the PRISMS study did not demonstrate the benefit of intravenous alteplase administration in patients with mild stroke within 3 h, about 30% of patients presenting with mild symptoms showed unfavorable functional outcomes. We investigated the factors predictive of functional disability at 90 days in patients who were excluded from alteplase administration due to the National Institutes of Health Stroke Scale (NIHSS) scores of 0\u20135 and a score between 0 and 2 for each NIHSS score item.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All patients were diagnosed with acute ischemic stroke or transient ischemic attack within 4.5 h of admission to a tertiary hospital and did not receive alteplase due to a minor stroke between January 2013 and December 2020. Radiological data and clinical information were collected, including baseline and discharge NIHSS scores and modified Rankin Scale (mRS) scores at 90 days. Early neurological deterioration (END) was defined as an increase of two or more NIHSS scores. We defined moderate motor weakness as a NIHSS limb motor score of more than 3 and defined a favorable outcome as a mRS score at 90 days that was 0 or 1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      During the investigation period, 400 patients did not receive alteplase. END occurred significantly more frequently in patients with large artery disease (LAD) than in those with other TOAST classifications. In the multivariate regression analysis, NIHSS per 1-point increase, presenting as moderate motor weakness, and LAD were independent predictors of poor functional outcome (OR, 1.811 NIHSS per 1-point increase; 95% confidence interval [CI], 1.503\u20132.182;\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.0001; OR, 2.173 moderate motor weakness; 95% CI 1.028\u20134.595;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.042; OR, 2.033 LAD; 95% CI 1.099\u20133.762;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.024, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Moderate motor weakness presentation and LAD may be important factors associated with poor functional outcomes in patients with acute stroke excluded from alteplase administration due to mild symptoms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2022.1062721","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T06:16:59Z","timestamp":1671689819000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Factors associated with functional disability in patients with acute stroke excluded from alteplase administration due to minor non-disabling neurological deficits"],"prefix":"10.3389","volume":"13","author":[{"given":"Yong Jin","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Hong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon-Mi","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Jin","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hoon","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","article-title":"Tissue plasminogen activator for acute ischemic stroke","volume":"333","year":"1995","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","article-title":"et al. Thrombolysis with alteplase 3 to 45 hours after acute ischemic stroke","volume":"359","author":"Hacke","year":"2008","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1001\/jama.274.13.1017","article-title":"Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)","volume":"274","author":"Hacke","year":"1995","journal-title":"JAMA."},{"key":"B4","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S1474-4422(08)70044-9","article-title":"Effects of alteplase beyond 3 h after stroke in the echoplanar imaging thrombolytic evaluation trial (EPITHET): a placebo-controlled randomised trial","volume":"7","author":"Davis","year":"2008","journal-title":"Lancet Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0140-6736(98)08020-9","article-title":"Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)","volume":"352","author":"Hacke","year":"1998","journal-title":"Second Eur Aust Acute Stroke Study Invest Lancet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1212\/WNL.0000000000003198","article-title":"Why are acute ischemic stroke patients not receiving IV tPA? Results from a national registry","volume":"87","author":"Mess\u00e9","year":"2016","journal-title":"Neurology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1161\/STROKEAHA.112.665141","article-title":"et al. What causes disability after transient ischemic attack and minor stroke? Results from the CT and MRI in the Triage of TIA and minor cerebrovascular events to identify high risk patients (CATCH) study","volume":"43","author":"Coutts","year":"2012","journal-title":"Stroke."},{"key":"B8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1161\/CIRCOUTCOMES.111.000095","article-title":"Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get with the guidelines\u2013stroke hospitals","volume":"6","author":"Schwamm","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"B9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jama.2018.8496","article-title":"Effect of alteplase vs. aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurological deficits: the prisms randomized clinical trial","volume":"320","author":"Khatri","year":"2018","journal-title":"JAMA."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1161\/STROKEAHA.119.027708","article-title":"Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke","volume":"50","author":"Warner","year":"2019","journal-title":"Stroke."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e70996","DOI":"10.1371\/journal.pone.0070996","article-title":"Proximal arterial occlusion in acute ischemic stroke with low NIHSS scores should not be considered as mild stroke","volume":"8","author":"Kim","year":"2013","journal-title":"PLoS ONE."},{"key":"B12","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1161\/STROKEAHA.110.593897","article-title":"Acute Stroke Accurate Prediction Study (ASAP) Investigators. Ninety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic stroke","volume":"43","author":"Khatri","year":"2012","journal-title":"Stroke."},{"key":"B13","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00415-018-09173-0","article-title":"Incidence and mechanism of early neurological deterioration after endovascular thrombectomy","volume":"266","author":"Kim","year":"2019","journal-title":"J Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1161\/STROKEAHA.119.028550","article-title":"Thrombolysis outcomes in acute ischemic stroke by fluid-attenuated inversion recovery hyperintense arteries","volume":"51","author":"Zhou","year":"2020","journal-title":"Stroke."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.01.027","article-title":"Utility of items of baseline National Institutes of Health stroke scale as predictors of functional outcomes at three months after mild ischemic stroke","volume":"26","author":"Choi","year":"2017","journal-title":"J Stroke Cerebrovasc Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1161\/STROKEAHA.109.572883","article-title":"What is a minor stroke?","volume":"41","author":"Fischer","year":"2010","journal-title":"Stroke."},{"key":"B17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1212\/WNL.0000000000000572","article-title":"Factors associated with unfavorable outcome in minor ischemic stroke","volume":"83","author":"Sato","year":"2014","journal-title":"Neurology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1019530","DOI":"10.3389\/fneur.2022.1019530","article-title":"Biomarker of early neurological deterioration in minor stroke and proximal large vessel occlusion","volume":"13","author":"Wang","year":"2022","journal-title":"Front Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1210\/clinem\/dgac176","article-title":"Early Warning of ischemic stroke based on atherosclerosis index combined with serum markers","volume":"107","author":"Zhou","year":"2022","journal-title":"J Clin Endocrinol Metabol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s12883-020-01907-w","article-title":"Asymmetrical cortical vein sign predicts early neurological deterioration in acute ischemic stroke patients with severe intracranial arterial stenosis or occlusion","volume":"20","author":"Li","year":"2020","journal-title":"BMC Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.21037\/apm-20-1175","article-title":"FLAIR vascular hyperintensity: an unfavorable marker of early neurological deterioration and short-term prognosis in acute ischemic stroke patients","volume":"9","author":"Zhu","year":"2020","journal-title":"Ann Palliat Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3174\/ajnr.A6142","article-title":"The association between FLAIR vascular hyperintensity and stroke outcome varies with time from onset","volume":"40","author":"Shang","year":"2019","journal-title":"AJNR Am J Neuroradiol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.1062721\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T06:17:00Z","timestamp":1671689820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.1062721\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":22,"alternative-id":["10.3389\/fneur.2022.1062721"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.1062721","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]},"article-number":"1062721"}}